CYBERKINETICS' ANDARA™ OFS™ DEVICE HONORED WITH NEUROTECH BUSINESS REPORT'S 'GOLD ELECTRODE AWARD' FOR BEST NEW PRODUCT

FOXBOROUGH, MA and SAN FRANCISCO, CA– September 28, 2006 - Cyberkinetics Neurotechnology Systems Inc. (OTCBB: CYKN) (Cyberkinetics) and *Neurotech Business Report* announced that Cyberkinetics' Andara™ Oscillating Field Stimulator (OFS™) Device will receive the publication's "Gold Electrode Award" for Best New Product on Friday, September 29, 2006, at the "Neurotech Leaders Forum 2006" at the Crowne Plaza San Francisco International Airport. The Andara™ OFS™ Device is designed to restore sensory and motor function in those with acute spinal cord injuries. Mark A. Carney, Cyberkinetics' Executive Vice President, will accept the award for Cyberkinetics.

"*Neurotech Reports'* editors believe the Andara™ OFS™ Device represents a groundbreaking advance in neurotechnology as potentially the first commercial neural regeneration stimulation system to reach the market," said James Cavuoto, editor and publisher of *Neurotech Reports*. "We were also impressed with the developers' efficient transition from university research to commercial development. Finally, we're pleased to see Cyberkinetics is pursuing this important market — offering hope and solid scientific progress for individuals paralyzed by spinal cord injuries."

"This award highlights the rapidly emerging clinical potential of our Andara™ OFS™ neural stimulation platform," added Timothy R. Surgenor, President and Chief Executive Officer of Cyberkinetics Neurotechnology Systems, Inc. "We are developing this technology as a treatment for the devastating effects of severe spinal cord injury. The Andara™ technology platform significantly broadens the franchise that we established with our BrainGate Neural Interface System for the potential treatment of those with nervous system injuries, diseases and conditions."

In selecting the winner of the "Gold Electrode Award" for Best New Product, editors of the *Neurotech Reports* considered a wide range of new technologies and product directions in the neurotechnology field. From among these, the editors singled out Cyberkinetics' Andara™ OFS™ Device as a product that has broken new ground in the treatment of acute spinal cord injury.

In 2005, John P. Donoghue, Ph.D., a founder of Cyberkinetics, received the *Neurotech Business Report's* "Gold Electrode Award" for Researcher of the Year based on his work in the field of brain-computer interfaces, including development of the BrainGate™ Neural Interface System.

About *Neurotech Reports* and the *Neurotech Business Report*
Neurotech Reports serves the scientific, medical engineering and financial communities interested in developing the new field of neurotechnology. *Neurotech Reports* is dedicated to providing business and technology professionals up-to-date and forward-looking information about the field of neurotechnology and future developments that will affect the venture capital, research, and start-up communities.

Neurotech Business Report is the first publication targeting the business of neurotechnology, the application of engineering techniques to human neural and information processing systems. The newsletter covers the ongoing technology transfer from medical devices to commercial products in emerging markets like computer interfaces and training/simulation, as well as technologies including neural prostheses, neural sensing and stimulation and brain-computer interfaces.

For more information, visit http://www.neurotechreports.com

About the Andara™ OFS™ Device

Cyberkinetics' Andara™ OFS™ Device is based on research by Richard Ben Borgens, Ph.D. The initial research was done by Dr. Borgens at the Center for Paralysis Research at Purdue University. The Andara™ OFS™ Device, about the size of a cardiac pacemaker, is intended to improve or restore tactile sensation and some movement in those with quadriplegia and tetraplegia due to recent spinal cord injuries by promoting nerve fiber regeneration. The Andara™ OFS™ Device has been shown in numerous published, randomized, controlled, preclinical studies to restore sensation and some motor function. Results of a ten-patient clinical study were published in the *Journal of Neurosurgery: Spine* in January of 2005.

Designated as an Humanitarian Use Device by the FDA on September 6, 2006, Cyberkinetics expects to file an Humanitarian Device Exemption (HDE) in the fourth quarter of 2006. If approved, Cyberkinetics could begin marketing the Andara™ OFS™ Device on a limited basis within 2007.

Forward Looking Safe Harbor Statement

This announcement contains forward-looking statements, including statements about Cyberkinetics' product development plans and progress, potential development of proprietary inventions and benefits that may be realized by certain research programs. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and can be identified by the use of forward-looking terminology such as "may," "will," "believe," "expect," "anticipate" or other comparable terminology. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements and reported results shall not be considered an indication of our future performance. Factors that might cause or contribute to such differences include our limited operating history; our lack of profits from operations; our ability to successfully develop and commercialize our proposed products; a lengthy approval process and the uncertainty of FDA and other governmental regulatory requirements; clinical trials may fail to demonstrate the safety and effectiveness of our products; the degree and nature of our competition; our ability to employ and retain qualified employees; compliance with recent legislation regarding corporate governance, including the Sarbanes-Oxley Act of 2002; as well as those risks more fully discussed in our public filings with the Securities and Exchange Commission, all of which are difficult to predict and some of which are beyond our control.

Cyberkinetics Contact:
Elizabeth A. Razee
Manager, Corporate Communications
508-549-9981, Ext. 109
erazee@cyberkineticsinc.com

***Neurotech Business Report* Contact:**
Carmen Caricchio, President
CoActive Public Relations
415-621-6626, Cell: 415-350-7050
carmen@coactivepr.com